These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 25081318)

  • 1. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation.
    Yuan H; Cai P; Li Q; Wang W; Sun Y; Xu Q; Gu Y
    Biomed Pharmacother; 2014 Jul; 68(6):751-6. PubMed ID: 25081318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity.
    Zhang X; Fang X; Gao Z; Chen W; Tao F; Cai P; Yuan H; Shu Y; Xu Q; Sun Y; Gu Y
    Anticancer Drugs; 2014 Feb; 25(2):204-11. PubMed ID: 24135499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained.
    Ko JS; Rayman P; Ireland J; Swaidani S; Li G; Bunting KD; Rini B; Finke JH; Cohen PA
    Cancer Res; 2010 May; 70(9):3526-36. PubMed ID: 20406969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Finke J; Ko J; Rini B; Rayman P; Ireland J; Cohen P
    Int Immunopharmacol; 2011 Jul; 11(7):856-61. PubMed ID: 21315783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
    Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
    PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib in the treatment of metastatic renal cell carcinoma.
    Ho TH; Jonasch E
    Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
    Harada M; Iida Y; Kotani H; Minami T; Komohara Y; Eto M; Yoshikawa K; Uemura H
    Cancer Immunol Immunother; 2022 Feb; 71(2):339-352. PubMed ID: 34160685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
    Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H
    Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axitinib for the treatment of advanced renal cell carcinoma.
    Akaza H; Fukuyama T
    Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.
    Zakharia Y; Zakharia K; Rixe O
    Expert Opin Drug Discov; 2015; 10(8):925-35. PubMed ID: 26039031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib for renal cell carcinoma.
    Sonpavde G; Hutson TE; Rini BI
    Expert Opin Investig Drugs; 2008 May; 17(5):741-8. PubMed ID: 18447599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomal Hsp70 mediates immunosuppressive activity of the myeloid-derived suppressor cells via phosphorylation of Stat3.
    Diao J; Yang X; Song X; Chen S; He Y; Wang Q; Chen G; Luo C; Wu X; Zhang Y
    Med Oncol; 2015 Feb; 32(2):453. PubMed ID: 25603952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
    Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
    Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
    Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
    Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corosolic acid impairs tumor development and lung metastasis by inhibiting the immunosuppressive activity of myeloid-derived suppressor cells.
    Horlad H; Fujiwara Y; Takemura K; Ohnishi K; Ikeda T; Tsukamoto H; Mizuta H; Nishimura Y; Takeya M; Komohara Y
    Mol Nutr Food Res; 2013 Jun; 57(6):1046-54. PubMed ID: 23417831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.